Healthcare [ 13/13 ] | Diagnostics & Research [ 77/164 ]
NASDAQ | Common Stock
LumiraDx Limited operates as a point of care diagnostics company.
The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers.
It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions.
Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease.
The company is headquartered in London, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 21.00 M - | -49.74 M - | Decreased by -236.80% - |
| Mar 31, 23 | 22.17 M - | -44.21 M - | Decreased by -199.39% - |
| Dec 31, 22 | 41.12 M - | -100.60 M - | Decreased by -244.66% - |